SK286245B6 - Farmaceutická kompozícia obsahujúca ziprasidon a spôsob výroby veľkých kryštálov monohydrátu hydrochloridu ziprasidonu - Google Patents

Farmaceutická kompozícia obsahujúca ziprasidon a spôsob výroby veľkých kryštálov monohydrátu hydrochloridu ziprasidonu Download PDF

Info

Publication number
SK286245B6
SK286245B6 SK769-99A SK76999A SK286245B6 SK 286245 B6 SK286245 B6 SK 286245B6 SK 76999 A SK76999 A SK 76999A SK 286245 B6 SK286245 B6 SK 286245B6
Authority
SK
Slovakia
Prior art keywords
composition
ziprasidone
particle size
mean
free base
Prior art date
Application number
SK769-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK76999A3 (en
Inventor
Frank Robert Busch
Angela Carol Gatlin Hausberger
Bijan Rasadi
Daniel Ray Arenson
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22216447&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK286245(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of SK76999A3 publication Critical patent/SK76999A3/sk
Publication of SK286245B6 publication Critical patent/SK286245B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
SK769-99A 1998-06-15 1999-06-09 Farmaceutická kompozícia obsahujúca ziprasidon a spôsob výroby veľkých kryštálov monohydrátu hydrochloridu ziprasidonu SK286245B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8922998P 1998-06-15 1998-06-15

Publications (2)

Publication Number Publication Date
SK76999A3 SK76999A3 (en) 2000-12-11
SK286245B6 true SK286245B6 (sk) 2008-06-06

Family

ID=22216447

Family Applications (1)

Application Number Title Priority Date Filing Date
SK769-99A SK286245B6 (sk) 1998-06-15 1999-06-09 Farmaceutická kompozícia obsahujúca ziprasidon a spôsob výroby veľkých kryštálov monohydrátu hydrochloridu ziprasidonu

Country Status (45)

Country Link
US (1) US6150366A (pt)
EP (1) EP0965343B1 (pt)
JP (2) JP3441676B2 (pt)
KR (1) KR100338915B1 (pt)
CN (1) CN1307994C (pt)
AP (1) AP1216A (pt)
AR (1) AR015553A1 (pt)
AT (1) ATE240732T1 (pt)
AU (1) AU753820B2 (pt)
BG (1) BG64691B1 (pt)
BR (1) BR9902268A (pt)
CA (1) CA2274338C (pt)
CO (1) CO5070579A1 (pt)
CY (1) CY2003002I1 (pt)
CZ (1) CZ297954B6 (pt)
DE (1) DE69908021T2 (pt)
DK (1) DK0965343T3 (pt)
EA (1) EA002223B1 (pt)
ES (1) ES2197581T3 (pt)
GT (1) GT199900080A (pt)
HK (1) HK1024184A1 (pt)
HN (1) HN1999000089A (pt)
HR (1) HRP990193B1 (pt)
HU (1) HU226487B1 (pt)
ID (1) ID23546A (pt)
IL (1) IL130424A (pt)
IS (1) IS2182B (pt)
MA (1) MA26647A1 (pt)
MY (1) MY121397A (pt)
NO (1) NO316713B1 (pt)
NZ (1) NZ336271A (pt)
OA (1) OA11064A (pt)
PA (1) PA8475601A1 (pt)
PE (1) PE20000632A1 (pt)
PL (2) PL195209B1 (pt)
PT (1) PT965343E (pt)
RS (1) RS49611B (pt)
SG (1) SG77243A1 (pt)
SI (1) SI0965343T1 (pt)
SK (1) SK286245B6 (pt)
TR (1) TR199901379A2 (pt)
TW (1) TW590774B (pt)
UA (1) UA59383C2 (pt)
UY (1) UY25649A1 (pt)
ZA (1) ZA993938B (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
WO2000072847A1 (en) * 1999-05-27 2000-12-07 Pfizer Products Inc. Ziprasidone suspension
US7175855B1 (en) 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
EP1623703B1 (en) 1999-10-29 2011-10-05 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR100968128B1 (ko) 2000-10-30 2010-07-06 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
CA2483464C (en) 2002-05-17 2011-12-20 Duke University Method for treating obesity
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
US7488729B2 (en) * 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
US20050143396A1 (en) * 2003-04-11 2005-06-30 Hertero Drugs Limited Novel crystalline forms of ziprasidone hydrochloride
EP2316456B1 (en) 2003-04-29 2017-06-14 Orexigen Therapeutics, Inc. Compositions for affecting weight loss comprising an opioid antagonist and bupropion
CA2528192A1 (en) * 2003-06-03 2005-02-24 Teva Pharmaceutical Industries Ltd Cristalline ziprasidone hcl and processes for preparation thereof
US20050049295A1 (en) * 2003-06-12 2005-03-03 Dr. Reddy's Laboratories Limited Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate
BRPI0414082A (pt) * 2003-09-02 2006-10-24 Pfizer Prod Inc formas de dosagem de liberação sustentada de ziprasidona
US7667037B2 (en) * 2003-10-24 2010-02-23 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
AU2003285600A1 (en) * 2003-11-28 2005-06-24 Siddiqui Mohammed Jaweed Mukarram Process for the preparing ziprasidone monohydrochloride hydrate
US20050197347A1 (en) * 2003-12-18 2005-09-08 Judith Aronhime Polymorphic form B2 of ziprasidone base
EP1703898A2 (en) * 2003-12-31 2006-09-27 Alpharma, Inc. Ziprasidone formulations
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
JP2007517901A (ja) * 2004-01-13 2007-07-05 デューク・ユニバーシティー 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
ATE451367T1 (de) * 2004-02-27 2009-12-15 Ranbaxy Lab Ltd Verfahren zur herstellung von ziprasidon
RU2006139930A (ru) * 2004-05-03 2008-06-10 Дюк Юниверсити (Сша/Сша) (Us) Составы для содействия снижению веса
WO2005107719A2 (en) * 2004-05-06 2005-11-17 Sandoz Ag Pharmaceutical composition comprising hydrophobic drug having improved solubility
CA2467538C (en) * 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
EP1753400A4 (en) * 2004-06-11 2012-11-28 Reddys Lab Ltd Dr PHARMACEUTICAL FOR ZIPRASIDONE
CA2471219A1 (en) * 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
WO2006026426A2 (en) * 2004-08-27 2006-03-09 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer’s disease peripherally
CN101123951A (zh) 2004-08-31 2008-02-13 辉瑞产品公司 包括低溶解性药物和聚合物的药物剂型
JP5324098B2 (ja) * 2004-11-16 2013-10-23 アルケルメス ファーマ アイルランド リミテッド 注射可能なナノ粒子のオランザピン製剤
WO2006085168A2 (en) * 2005-01-07 2006-08-17 Ranbaxy Laboratories Limited Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
US7749529B2 (en) * 2005-02-08 2010-07-06 Ash Access Technology, Inc. Catheter lock solution comprising citrate and a paraben
EP1863806A1 (en) * 2005-02-11 2007-12-12 Teva Pharmaceutical Industries Ltd Amorphous ziprasidone mesylate
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) * 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
WO2006099452A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Anhydrous ziprasidone mesylate and a process for its preparation
US20060270684A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Crystalline forms of ziprasidone mesylate
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
RU2407529C2 (ru) * 2005-04-13 2010-12-27 Пфайзер Продактс Инк. Инъецируемые препаративные формы депо и способы обеспечения замедленного высвобождения композиций, состоящих из наночастиц
TW200716091A (en) * 2005-04-22 2007-05-01 Wyeth Corp New therapeutic combinations for the treatment or prevention of psychotic disorders
ES2535478T3 (es) 2005-05-26 2015-05-12 Sumitomo Dainippon Pharma Co., Ltd. Composición farmacéutica
KR20080024206A (ko) * 2005-06-20 2008-03-17 엘란 파마 인터내셔널 리미티드 아릴-헤테로시클릭 화합물을 함유하는 나노입자형 조절방출 조성물
CN101242813A (zh) * 2005-06-20 2008-08-13 依兰药物国际有限公司 包含芳基-杂环化合物的毫微粒和控制释放组合物
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
EP1954241B1 (en) * 2005-11-28 2012-02-29 Orexigen Therapeutics, Inc. Sustained-release formulation of zonisamide
PL379569A1 (pl) * 2006-04-28 2007-10-29 Pliva Kraków Zakłady Farmaceutyczne Spółka Akcyjna Sposób wytwarzania kompozycji farmaceutycznej zawierającej substancję aktywną ziprasidone lub jego farmaceutycznie dopuszczalną sól zwiększający rozpuszczalność i biodostępność tego leku, kompozycja farmaceutyczna i zastosowanie hydrofilowych substancji pomocniczych
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1892243A1 (en) * 2006-08-02 2008-02-27 KRKA, tovarna zdravil, d.d., Novo mesto Polymorphic forms of ziprasidone sulphate salts
EP1889844A3 (en) * 2006-08-02 2008-03-05 Krka Polymorphic forms of ziprasidone sulphates
AR063958A1 (es) 2006-11-09 2009-03-04 Orexigen Therapeutics Inc Metodos para administrar medicaciones para la perdida de peso
CA2668884C (en) 2006-11-09 2016-11-01 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
MX2009011681A (es) * 2007-05-18 2009-11-10 Scidose Llc Formulaciones de ziprasidona.
EP2197446A4 (en) * 2007-08-31 2012-01-25 Reddys Lab Ltd Dr PREPARATION OF HYDROCHLORIDE OF ZIPRASIDONE MONOHYDRATE
US8410268B2 (en) * 2008-03-11 2013-04-02 Alkem Laboratories Limited Process for the preparation of ziprasidone
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
DE102008045854A1 (de) 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung
EP2445343B1 (en) 2009-06-25 2021-08-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
EP2340834A1 (en) 2009-12-30 2011-07-06 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Enhanced Solubility of Ziprasidone
EP3659604A1 (en) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
EP3257500B1 (en) 2010-02-25 2019-10-16 Bristol-Myers Squibb Holdings Ireland Unlimited Company Apixaban formulations
US20130108701A1 (en) 2010-05-25 2013-05-02 Krishna Murthy Bhavanasi Solid Dosage Forms of Antipsychotics
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
CN110893181A (zh) 2012-06-06 2020-03-20 纳丙药业有限责任公司 治疗超重和肥胖症的方法
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2019173230A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264446A (en) * 1980-09-09 1993-11-23 Bayer Aktiengesellschaft Solid medicament formulations containing nifedipine, and processes for their preparation
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
DE4141268A1 (de) * 1991-12-14 1993-06-17 Merck Patent Gmbh Pharmazeutische zubereitung
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5338846A (en) * 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
DK0790236T3 (da) * 1996-02-13 2004-02-23 Pfizer Prolægemidler af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor-1,3-dihydro-2H-indol-2-on
DK0901786T3 (da) * 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed

Also Published As

Publication number Publication date
ID23546A (id) 2000-05-04
EP0965343A2 (en) 1999-12-22
CA2274338C (en) 2003-04-15
OA11064A (en) 2002-03-13
EP0965343B1 (en) 2003-05-21
IL130424A (en) 2003-10-31
HU9901960D0 (en) 1999-08-30
AU3398399A (en) 1999-12-23
NO992892D0 (no) 1999-06-14
AP9901579A0 (en) 1999-06-30
PT965343E (pt) 2003-08-29
TR199901379A2 (xx) 2000-01-21
RS49611B (sr) 2007-06-04
AR015553A1 (es) 2001-05-02
CZ297954B6 (cs) 2007-05-09
BG103489A (en) 2000-07-31
DE69908021T2 (de) 2003-11-27
SG77243A1 (en) 2000-12-19
JP2000007566A (ja) 2000-01-11
HRP990193B1 (en) 2003-08-31
EP0965343A3 (en) 2000-02-23
EA199900467A3 (ru) 2000-04-24
HUP9901960A3 (en) 2000-09-28
NO316713B1 (no) 2004-04-13
BR9902268A (pt) 2000-05-02
DE69908021D1 (de) 2003-06-26
UA59383C2 (uk) 2003-09-15
NO992892L (no) 1999-12-16
JP4187423B2 (ja) 2008-11-26
EA199900467A2 (ru) 1999-12-29
ATE240732T1 (de) 2003-06-15
SK76999A3 (en) 2000-12-11
IS2182B (is) 2006-12-15
PA8475601A1 (es) 2000-09-29
JP3441676B2 (ja) 2003-09-02
KR20000006143A (ko) 2000-01-25
HK1024184A1 (en) 2000-10-05
PL195606B1 (pl) 2007-10-31
PL195209B1 (pl) 2007-08-31
BG64691B1 (bg) 2005-12-30
HU226487B1 (en) 2009-03-02
AP1216A (en) 2003-10-19
AU753820B2 (en) 2002-10-31
YU27199A (sh) 2002-12-10
MA26647A1 (fr) 2004-12-20
EA002223B1 (ru) 2002-02-28
ES2197581T3 (es) 2004-01-01
JP2002003492A (ja) 2002-01-09
HUP9901960A2 (hu) 2000-08-28
CA2274338A1 (en) 1999-12-15
PL333737A1 (en) 1999-12-20
TW590774B (en) 2004-06-11
IL130424A0 (en) 2000-06-01
GT199900080A (es) 2000-11-29
DK0965343T3 (da) 2003-08-04
CY2003002I1 (el) 2009-11-04
CO5070579A1 (es) 2001-08-28
PE20000632A1 (es) 2000-07-26
UY25649A1 (es) 2000-02-23
CN1242987A (zh) 2000-02-02
ZA993938B (en) 2000-12-14
HRP990193A2 (en) 2000-02-29
KR100338915B1 (ko) 2002-05-30
US6150366A (en) 2000-11-21
NZ336271A (en) 2000-10-27
SI0965343T1 (en) 2003-10-31
HN1999000089A (es) 1999-11-03
CN1307994C (zh) 2007-04-04
MY121397A (en) 2006-01-28
CZ212799A3 (cs) 2000-09-13
IS5079A (is) 1999-12-16

Similar Documents

Publication Publication Date Title
SK286245B6 (sk) Farmaceutická kompozícia obsahujúca ziprasidon a spôsob výroby veľkých kryštálov monohydrátu hydrochloridu ziprasidonu
US20200375968A1 (en) Apixaban formulations
EP2623100B1 (en) Preparation for improving solubility of poorly soluble drug
EP1574215B1 (en) Solid drug for oral use
US20130084335A1 (en) Ivabradine-containing pharmaceutical composition
US20100034885A1 (en) Formulations containing glimepiride and/or its salts
US20210401748A1 (en) Powder for oral suspension containing lamotrigine
CN109260207A (zh) 嘧啶二酮衍生物化合物的制剂
US20220323358A1 (en) Powder for oral suspension containing tadalafil
US20220073474A1 (en) Pharmaceutical compound, the method of its making and use as medicinal agent
AU2017228681B2 (en) Apixaban formulations
MXPA99005524A (en) Ziprasid formulations
US20050129768A1 (en) Pharmaceutical formulation containing an LTB4-antagonist, as well as processes for the preparation thereof and the use thereof

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20130609